Inflammation and Angiogenesis in Diabetic Retinopathy
Ying Yang,Ying Zhang,Yiping Li
DOI: https://doi.org/10.5772/29521
2012-01-01
Abstract:IntroductionDiabetic retinopathy (DR) is a significant cause of global blindness; a major cause of blindness in the world.There is emerging evidence that retinopathy is initiated and propagated by inflammation and angiogenesis.Increased cytokines and growth factors, in conjunction with redox stress, contribute to the development and progression of DR of abnormalities of endothelial cells and pericytes in DR.The four traditional metabolic pathways involved in the development of DR include: increased polyol pathway flux, advanced glycation end-product formation, activation of protein kinase Cisoforms and hexosamine pathway flux.These pathways individually and synergistically contribute to angiogenic growth factors, anti-angiogenic factors resulting in significant microvascular blood retinal barrier remodeling.The pathways are associated with inflammation and angiogenesis,either.Preventing or delaying the blindness associated with these intersecting abnormal metabolic pathways may be approached through strategies targeted to reduction of tissue inflammation.Understanding these abnormal metabolic pathways and the accompanying inflammation and angiogenesis mayprovide both the clinician and researcher a new concept of approaching this complicated disease process. Diabetic Retinopathy (DR)DR is associated with the following structural features: basement membrane (BM) thickening, pericyte loss,microaneurysms, intraretinal microvascular abnormalities(IRMA), diabetic macular edema (DME) and pre-retinal neovascularization,processes which can lead to blindness through hemorrhage and tractional retinal detachment 1 .Retinal endothelial cells (EC) are supported and sealed by a nearly equal number of pericytes in the retinal optic nerve fiber, inner and outer plexiform and choroidal layers creating a blood retinal barrier (BRB) of closed capillaries 1,2 .The vascular disruptions of DR/DME are characterized by abnormal vascular flow, disruptions in permeability,and/or closure or nonperfusion of capillaries.www.intechopen.comDiabetic Retinopathy 164A hallmark of early DR is the change in the structure and cellular composition of the microvasculature 3 .In early stages of DME, breakdown of the inner blood-retinal barrier may occur, resulting in accumulation of extracellular fluid in the macula 4,5 .Pericytes are essential cellular components in the regulation of retinal capillary perfusion, and damage to these cells in diabetes leads to altered retinal hemodynamics, including abnormal autoregulation of retinal blood flow 6 .Loss of retinal pericytes represents another early microaneurysm formation [7][8][9] .There is evidence that retinal leukostasis may also play an important role in the pathogenesis of DR.Leukocytes possess large cell volume, high cytoplasmic rigidity, a natural tendency to adhere to the vascular endothelium, and a capacity to generate toxic superoxide radicals and proteolytic enzymes 10 .In diabetes,there is increased retinal leukostasis, which affects retinal endothelial function, retinal perfusion, angiogenesis, and vascular permeability.And, leukocytes in diabetes are less deformable, a higher proportion are activated, and they may be involved in capillary nonperfusion, endothelial cell damage, and vascular leakage in the retinal microcirculation 10 .A study showed that diabetic vascular leakage and nonperfusion are temporally and spatially associated with retinal leukostasis in streptozotocin induced diabetic rats 11 .There are many capillary occlusions by leukocytes and capillary dropout or degeneration associated with leukocytes in the diabetic retina 10 .Serial acridine orange leukocyte fluorography and fluorescein angiography(FA) show trapped leukocytes directly associated with areas of downstream nonperfusion in the diabetic retinal microcirculation 10 .A number of proangiogenic, angiogenic and antiangiogenic factors are involved in the pathogenesis and progression of diabetic retinal disease, Vascular Endothelial Growth Factor (VEGF) being one of the most important.Other growth factors, which are known to participate in the pathogenesis of the disease, are: Platelet Derived Growth Factor (PDGF), Fibroblast Growth Factor (FGF), Hepatocyte Growth Factor (HGF), Transforming Growth Factor (TGF), Placental Endothelial Cell Growth Factor (PlGF), Connective Tissue Growth Factor (CTGF).Other molecules that are involved in the disease mechanisms are: intergrins, angiopoietins, protein kinase C (PKC), ephrins, interleukins, leptin, angiotensin, monocyte chemotactic protein (MCP), vascular cell adhesion molecule (VCAM), tissue plasminogen activator (TPA), and extracellular matrix metalloproteinases (ECM-MMPs). Vascular Endothelial Growth Factor (VEGF)The VEGFs are a family of proteins that are mitogenic for vascular endothelial cells and increase vascular permeability.VEGF is important in fetal vascular development,with VEGF levels diminishing after birth.VEGF is expressed by retinal glial cells 12 and vascular endothelial cells 13 .VEGF is secreted by numerous ocular cell types 14 , and increased levels of VEGF have been detected in ocular fluids of patients with proliferative diabetic retinopathy 15 .In vivo, administration of neutralizing VEGF antibodies to experimental animals reverses high-glucose-induced vascular hyperpermeability 16 , which is an early manifestation of endothelial dysfunction in diabetic patients 17 .VEGF expression is regulated largely by hypoxia, but it also accumulates in the retina early in diabetes, before any retinal hypoxia is yet apparent [18][19][20] .It is produced by multiple cell www.intechopen.comInflammation and Angiogenesis in Diabetic Retinopathy 165 types in the retina in diabetes, including ganglion cells, Mueller cells, and pericytes.Repeated injections of high concentrations of VEGF in the eyes of nondiabetic monkeys result in retinal changes which in some ways resemble those in the early stages of diabetic retinopathy, including vascular tortuosity and microaneurysm 21,22 .Genetic factors are important in the pathogenesis of DR; there is a clear association of increased expression of VEGF with DR as well as numerous VEGF polymorphisms that are linked to increased VEGF levels and DR. 23Their result has demonstrated that the development of different stages of diabetic retinopathy is closely correlated with an increased VEGF level in the retina 24 .Clinical trials using anti-VEGF therapies are showing promising results against stages of diabetic retinopathy 25 .VEGF is a potent vascular permeability factor, and VEGF upregulation has been linked to neovascular eye diseases including diabetic retinopathy 23 .VEGF-induced neovascular changes have previously been demonstrated on animal models based on increasing VEGF levels through implants 26 , recombinant adenovirus-mediated VEGF expression 27,28 , or transgenic technologies 29,30 .In the eye, one of the earliest signs of diabetic retinopathy is retinal capillary occlusion, blocking blood flow and generating capillary-free areas 31 .Hypoxic conditions could develop in these capillary-free areas, and this in turn could induce the upregulation of angiogenic factor production, such as VEGF and intercellular adhesion molecules 32,33 .The increased concentration of angiogenic factors would then cause vascular changes including vascular dilatations, tortuous blood vessels, microaneurysms, and endothelial cell proliferation.Subsequently,over an extended period of time, these changes could result in the development of poorly matured leaky vessels 34,35 .Previous histological studies have demonstrated a strong correlation between endothelial cell proliferation, pericyte loss, and the development of microaneurysm 36 .Incidentally, VEGF, which is a known factor of endothelial cell proliferation, has also been shown to promote pericyte detachment and loss 37 .Troglitazone and rosiglitazone, another thiazolidinediones (TZD), increase VEGF mRNA levels in 3T3-L1 adipocytes.Although increased VEGF may be beneficial for subjects with macroangiopathy and troglitazone is currently not available for clinical use, vascular complications, especially diabetic retinopathy, must be followed with great caution in subjects treated with TZD 38 . How to referenceIn order to correctly reference this scholarly work, feel free to copy and paste the following: